Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Preventing COVID-19 spread in closed facilities by regular testing of employees-An efficient intervention in long-term care facilities and prisons?

Tytuł:
Preventing COVID-19 spread in closed facilities by regular testing of employees-An efficient intervention in long-term care facilities and prisons?
Autorzy:
Tsoungui Obama HCJ; Department of Applied Computer- and Biosciences, University of Applied Sciences Mittweida, Mittweida, Germany.
Adil Mahmoud Yousif N; Department of Applied Computer- and Biosciences, University of Applied Sciences Mittweida, Mittweida, Germany.
Alawam Nemer L; African Institute for Mathematical Sciences Cameroon, Limbe, Cameroon.
Ngougoue Ngougoue PM; Department of Applied Computer- and Biosciences, University of Applied Sciences Mittweida, Mittweida, Germany.
Ngwa GA; Department of Applied Computer- and Biosciences, University of Applied Sciences Mittweida, Mittweida, Germany.; Department of Mathematics, University of Buea, Buea, Cameroon.
Teboh-Ewungkem M; Department of Mathematics, Lehigh University, Bethlehem, Pennsylvania, United States of America.
Schneider KA; Department of Applied Computer- and Biosciences, University of Applied Sciences Mittweida, Mittweida, Germany.
Źródło:
PloS one [PLoS One] 2021 Apr 22; Vol. 16 (4), pp. e0249588. Date of Electronic Publication: 2021 Apr 22 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Nursing Homes*
Prisons*
COVID-19/*diagnosis
COVID-19/*prevention & control
COVID-19 Testing ; Humans ; Long-Term Care ; Mass Screening ; SARS-CoV-2/isolation & purification
References:
JAMA. 2020 May 12;323(18):1760-1761. (PMID: 32259189)
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):100-105. (PMID: 33476316)
Am J Crim Justice. 2020;45(4):780-792. (PMID: 32837163)
Nature. 2021 Jan;589(7843):500-501. (PMID: 33479534)
BMJ. 2020 May 15;369:m1932. (PMID: 32414712)
JAMA Intern Med. 2020 Aug 1;180(8):1041-1042. (PMID: 32343355)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Nat Biomed Eng. 2020 Dec;4(12):1140-1149. (PMID: 32848209)
Lancet Infect Dis. 2020 Sep;20(9):e238-e244. (PMID: 32628905)
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1730-1735. (PMID: 33211679)
Infection. 2021 Feb;49(1):15-28. (PMID: 32860214)
Autoimmun Rev. 2020 Jul;19(7):102568. (PMID: 32376398)
BMC Infect Dis. 2020 Nov 19;20(1):859. (PMID: 33213360)
PLoS One. 2021 Jul 16;16(7):e0253758. (PMID: 34270576)
Euro Surveill. 2020 Jun;25(22):. (PMID: 32524949)
J Infect Dis. 2021 Apr 8;223(7):1139-1144. (PMID: 33394052)
Int J Infect Dis. 2020 Jun;95:311-315. (PMID: 32234343)
Afr J Prim Health Care Fam Med. 2020 Jul 27;12(1):e1-e3. (PMID: 32787397)
Health Aff (Millwood). 2020 Aug;39(8):1412-1418. (PMID: 32496864)
BMJ. 2020 Aug 13;370:m3218. (PMID: 32816748)
J Infect. 2021 Apr;82(4):e27-e28. (PMID: 33383088)
Int J Antimicrob Agents. 2020 Mar;55(3):105924. (PMID: 32081636)
J Math Biol. 1990;28(4):365-82. (PMID: 2117040)
Proc Natl Acad Sci U S A. 2021 Jan 7;118(1):. (PMID: 33323525)
Clin Transl Med. 2020 Jun;10(2):e44. (PMID: 32508062)
PLoS Pathog. 2020 Aug 27;16(8):e1008705. (PMID: 32853291)
Lancet Infect Dis. 2020 Apr;20(4):425-434. (PMID: 32105637)
Lancet Infect Dis. 2020 Jun;20(6):669-677. (PMID: 32240634)
PLoS One. 2021 Mar 31;16(3):e0248921. (PMID: 33788882)
N Engl J Med. 2020 May 21;382(21):2005-2011. (PMID: 32220208)
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):504-513. (PMID: 32834983)
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):587-590. (PMID: 32407300)
PLoS One. 2021 Apr 22;16(4):e0245417. (PMID: 33886573)
BMC Public Health. 2019 Aug 13;19(1):1090. (PMID: 31409319)
J Infect Chemother. 2021 Jun;27(6):890-894. (PMID: 33727026)
Appl Geogr. 2020 Dec;125:102363. (PMID: 33162624)
Infect Control Hosp Epidemiol. 2021 Jan;42(1):75-83. (PMID: 33028441)
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705. (PMID: 32845525)
J Infect. 2021 May;82(5):186-230. (PMID: 33421447)
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16. (PMID: 32425996)
Sci Rep. 2021 Feb 19;11(1):4263. (PMID: 33608563)
Euro Surveill. 2020 Mar;25(10):. (PMID: 32183930)
Innovation (Camb). 2020 May 21;1(1):100003. (PMID: 33554184)
Entry Date(s):
Date Created: 20210422 Date Completed: 20210504 Latest Revision: 20240401
Update Code:
20240401
PubMed Central ID:
PMC8062045
DOI:
10.1371/journal.pone.0249588
PMID:
33886605
Czasopismo naukowe
Background: Different levels of control measures were introduced to contain the global COVID-19 pandemic, many of which have been controversial, particularly the comprehensive use of diagnostic tests. Regular testing of high-risk individuals (pre-existing conditions, older than 60 years of age) has been suggested by public health authorities. The WHO suggested the use of routine screening of residents, employees, and visitors of long-term care facilities (LTCF) to protect the resident risk group. Similar suggestions have been made by the WHO for other closed facilities including incarceration facilities (e.g., prisons or jails), wherein parts of the U.S., accelerated release of approved inmates is taken as a measure to mitigate COVID-19.
Methods and Findings: Here, the simulation model underlying the pandemic preparedness tool CovidSim 1.1 (http://covidsim.eu/) is extended to investigate the effect of regularly testing of employees to protect immobile resident risk groups in closed facilities. The reduction in the number of infections and deaths within the risk group is investigated. Our simulations are adjusted to reflect the situation of LTCFs in Germany, and incarceration facilities in the U.S. COVID-19 spreads in closed facilities due to contact with infected employees even under strict confinement of visitors in a pandemic scenario without targeted protective measures. Testing is only effective in conjunction with targeted contact reduction between the closed facility and the outside world-and will be most inefficient under strategies aiming for herd immunity. The frequency of testing, the quality of tests, and the waiting time for obtaining test results have noticeable effects. The exact reduction in the number of cases depends on disease prevalence in the population and the levels of contact reductions. Testing every 5 days with a good quality test and a processing time of 24 hours can lead up to a 40% reduction in the number of infections. However, the effects of testing vary substantially among types of closed facilities and can even be counterproductive in U.S. IFs.
Conclusions: The introduction of COVID-19 in closed facilities is unavoidable without a thorough screening of persons that can introduce the disease into the facility. Regular testing of employees in closed facilities can contribute to reducing the number of infections there, but is only meaningful as an accompanying measure, whose economic benefit needs to be assessed carefully.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies